Loading...
•
Mar 31, 2021
Celsion Q1 2021 Earnings Report
Reported financial results for Q1 2021 and provided a business update, focusing on immuno-oncology and next-generation vaccines.
Key Takeaways
Celsion reported a net loss of $5.7 million, or $0.09 per share, for the first quarter of 2021. The company focused on immuno-oncology and next-generation vaccines, extended its cash operating runway through 2024, and strengthened its balance sheet by raising over $58 million in gross proceeds.
OVATION 2 Study is more than 40% enrolled with 23 clinical sites activated, and enrollment is expected to be completed before the end of 2021.
Announced an initiative to focus on DNA vaccine development leveraging the TheraPlas platform.
Received FDA Fast Track Designation for GEN-1 in Advanced Ovarian Cancer.
Filed a provisional U.S. patent application for a novel DNA-based vaccine for preventing or treating infections from a broad range of infectious agents.
Celsion
Celsion
Forward Guidance
Celsion believes it has sufficient capital resources to fund its operations through 2024.